Front. Immunol.Frontiers in ImmunologyFront. Immunol.1664-3224Frontiers Media S.A.10.3389/fimmu.2021.843461ImmunologyCorrectionCorrigendum: Impact of NK Cell Activating Receptor Gene Variants on Receptor Expression and Outcome of Immunotherapy in Acute Myeloid LeukemiaHusseinBrwa Ali12HallnerAlexander13WennströmLovisa4BruneMats4MartnerAnna13HellstrandKristoffer13BernsonElin15ThorénFredrik B.12*1Tumor Immunology (TIMM) Laboratory at Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg, Sweden2Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden3Department of Infectious Diseases, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden4Department of Hematology, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden5Department of Obstetrics and Gynecology, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden
Edited and reviewed by: Katy Rezvani, University of Texas MD Anderson Cancer Center, United States
*Correspondence: Fredrik B. Thorén, fredrik.thoren@gu.se
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
A Corrigendum on Impact of NK Cell Activating Receptor Gene Variants on Receptor Expression and Outcome of Immunotherapy in Acute Myeloid Leukemia by Hussein BA, Hallner A, Wennström L, Brune M, Martner A, Hellstrand K, et al. (2021). Front. Immunol. 12:5300. doi: 10.3389/fimmu.2021.796072NK cell receptorsgene variantssingle nucleotide polymorphismacute myeloid leukemiahistamine/IL-2Re:Mission trialimmunotherapy
In the original article, there was an error regarding Figure 3D as published. For purpose of clarification, AML patients enrolled in Re:Mission trial supposed to be divided into two groups based on NKp30 rs986475 gene variants (0=No G allele or 1=G allele carriers) in this Figure 3D but there is a third arm in the figure which is a patient with a zero value of NKp30 MFI and this was mistakenly added in GraphPad prism. The corrected version of Figure 3 appears below.
Impact of NKp30 rs986475 gene polymorphism on expression of NKp30 and clinical outcome of AML during immunotherapy. (A–D) Median fluorescence intensity of NKp30 based on genotype status of NKp30 rs986475 in AML patients in both CD16- CD56bright and CD16+ CD56+ NK cells before and after receiving one cycle of HDC/IL-2 therapy. Patients are divided according to presence (14 out of 61 before therapy, and 15 out of 62 after therapy) or absence of G allele in figures (A–D). (E, F) Kaplan-Meier curves show impact of different NKp30 rs986475 genotypes on leukemia-free survival (LFS) and overall survival (OS) of AML patients after receiving HDC/IL-2 therapy. Simple linear regression was applied to investigate impact of NKp30 gene variants on NKp30 expression both before and after immunotherapy in various NK subsets as shown in figures (A–D). Logrank test was used to analyze the survival based on NKp30 gene variants in figures (E, F).
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.